Clinical Trial Update: An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy [Phase 2]

View source ↗

Summary

This is a Phase 2 extension trial to re-treat relapsed or refractory multiple myeloma patients with bortezomib who previously participated in a Phase I/II study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED